Optimising chemotherapy dose density and dose intensitynew strategies to improve outcomes in adjuvant therapy for breast cancer

European Journal of Cancer

Volumn 36, Issue SUPPL. 1, 2000, Pages 1-3

  Gianni, A M ^a   Piccart, M J ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; DRUG ADMINISTRATION; DRUG DOSE; FEMALE; HUMAN; NEUTROPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0034001061     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00258-0     Document Type: Article

References (17)

1. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994, 12 , 2471–2508.
2. DeVita VT Jr. Principles of cancer management: chemotherapy. In DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology , 5th edn. Philadelphia, Lippincott-Raven, 1997, 333–347.
3. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997, 24 (Suppl. 10), S10-3–S10-10.
4. Skipper H. Data and analyses having to do with the influence of dose intensity and duration of treatment (single drugs and combinations) on lethal toxicity and therapeutic response of experimental neoplasms. Southern Research Institute Booklet 13 . Birmingham, Alabama, USA, Southern Research Institute, 24 December 1986. [NB - the reference is the whole booklet.]
5. W. Hryniuk M.N. Levine Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer J. Clin. Oncol. 4 1986 1162 1170
6. W. Hryniuk H. Bush The importance of dose intensity in chemotherapy of metastatic breast cancer J. Clin. Oncol. 2 1984 1281 1287
7. W.M. Hryniuk Average relative dose intensity and the impact on design of clinical trials Semin. Oncol. 14 1987 65 74
8. Hryniuk W, Frei E 3rd, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol 1998, 16 , 3137–3147.
9. I.F. Tannock N.F. Boyd G. DeBoer A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer J. Clin. Oncol. 6 1988 1377 1387
10. W.C. Wood D.R. Budman A.H. Korzun Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N. Engl. J. Med. 330 1994 1253 1259
11. D.R. Budman D.A. Berry C.T. Cirrincione Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer J. Natl. Cancer Inst. 90 1998 1205 1211
12. G. Bonadonna P. Valagussa A. Moliterni Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer N. Engl. J. Med. 332 1995 901 906
13. A. Goldhirsch A.S. Coates M. Colleoni Adjuvant chemoendocrine therapy in postmenopausal breast cancer cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference J. Clin. Oncol. 16 1998 1358 1362
14. Untch M. Dose-intensification (DI) of anthracycline in the adjuvant treatment of high-risk breast cancer (HRBC) and c-erbB-2 overexpression. Proc Am Soc Clin Oncol 1998, 17 , 103a (abstract 395).
15. R. Pettengell H. Gurney J.A. Radford Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma a randomized controlled trial Blood 80 1992 1430 1436
16. V. Trillet-Lenoir J. Green C. Manegold Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy Eur. J. Cancer 29A 1993 319 324
17. Therasse P, Mauriac L, Welnicka M. Neo-adjuvant chemotherapy in locally advanced breast cancer (LABC): an EORTC-NCIC-SAKK randomized phase III study comparing FEC (FU, epirubicin, cyclophosphamide) vs high-dose intensity EC+G-CSF (Filgrastim). Proc Am Soc Clin Oncol 1998, 17 , 124a (abstract 472).